Comparative Pharmacology
Head-to-head clinical analysis: BRETHAIRE versus ISOETHARINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETHAIRE versus ISOETHARINE HYDROCHLORIDE.
BRETHAIRE vs ISOETHARINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
ISOETHARINE HYDROCHLORIDE is a beta-2 adrenergic receptor agonist that stimulates adenylate cyclase, increasing cyclic AMP (cAMP) in bronchial smooth muscle, leading to bronchodilation. It also has beta-1 activity at higher doses, causing cardiac stimulation.
2 inhalations (370 mcg each) by oral inhalation 4 times daily as needed; maximum 12 inhalations per day.
Inhalation via nebulizer: 0.5 mL (2.5 mg) of 0.5% solution diluted in 2-3 mL normal saline, administered over 10-20 minutes, every 4-6 hours as needed.
None Documented
None Documented
3.8 hours (terminal elimination half-life; clinical context: dosing interval typically every 4-6 hours)
1.6 to 2.7 hours in adults; may be prolonged in patients with hepatic or renal impairment.
Renal (25% unchanged, 75% as inactive sulfate conjugates), biliary/fecal (minimal)
Primarily renal excretion of unchanged drug and metabolites; approximately 60-80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist